198 related articles for article (PubMed ID: 23136730)
21. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction.
Balestreri R; Fontana L; Astengo F
J Am Geriatr Soc; 1987 May; 35(5):425-30. PubMed ID: 3553281
[TBL] [Abstract][Full Text] [Related]
22. Protective effect of vinpocetine against brain damage caused by ischemia.
Rischke R; Krieglstein J
Jpn J Pharmacol; 1991 Jul; 56(3):349-56. PubMed ID: 1895579
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study.
Cotroneo AM; Castagna A; Putignano S; Lacava R; Fantò F; Monteleone F; Rocca F; Malara A; Gareri P
Clin Interv Aging; 2013; 8():131-7. PubMed ID: 23403474
[TBL] [Abstract][Full Text] [Related]
24. [Effect of vinpocetin on the hemorheologic parameters in patients with chronic cerebrovascular disease].
Szapáry L; Horváth B; Alexy T; Márton Z; Késmárky G; Szóts M; Nagy F; Czopf J; Tóth K
Orv Hetil; 2003 May; 144(20):973-8. PubMed ID: 12830727
[TBL] [Abstract][Full Text] [Related]
25. Vinpocetine. Monograph.
Altern Med Rev; 2002 Jun; 7(3):240-3. PubMed ID: 12126465
[No Abstract] [Full Text] [Related]
26. The effect of vinpocetine on cerebral blood flow in patients with cerebrovascular disorders.
Tamaki N; Kusunoki T; Matsumoto S
Ther Hung; 1985; 33(1):13-21. PubMed ID: 3841996
[No Abstract] [Full Text] [Related]
27. [Multicenter observational program for evaluation of the effectiveness of the recognan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology].
Mashin VV; Belova LA; Bakhtogarimov IR; Bergelson TM; Sharafutdinova RR
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(8):39-43. PubMed ID: 28884715
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic effect of piracetam with nimodipine on vascular dementia after cerebral infarction.
Zongfang Z; Wenjing L; Zhaomin C; Lei Z
Pak J Pharm Sci; 2020 Sep; 33(5(Special)):2405-2411. PubMed ID: 33832882
[TBL] [Abstract][Full Text] [Related]
29. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment.
Alvarez-Sabín J; Ortega G; Jacas C; Santamarina E; Maisterra O; Ribo M; Molina C; Quintana M; Román GC
Cerebrovasc Dis; 2013; 35(2):146-54. PubMed ID: 23406981
[TBL] [Abstract][Full Text] [Related]
30. Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis.
Taguchi A; Takata Y; Ihara M; Kasahara Y; Tsuji M; Nishino M; Stern D; Okada M
Psychogeriatrics; 2013 Sep; 13(3):164-9. PubMed ID: 25707423
[TBL] [Abstract][Full Text] [Related]
31. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial.
Lin CH; Chen PK; Chang YC; Chuo LJ; Chen YS; Tsai GE; Lane HY
Biol Psychiatry; 2014 May; 75(9):678-85. PubMed ID: 24074637
[TBL] [Abstract][Full Text] [Related]
32. [Ceraxon (citicoline) in the treatment of the mild cognitive impairment syndrome].
Gavrilova SI; Fedorova IaB; Gantman ; Kalyn IaB; Kolykhalov IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):16-20. PubMed ID: 22433803
[TBL] [Abstract][Full Text] [Related]
33. [Effect of cavinton forte on the cerebral hemodynamic and autoregulation mechanisms of cerebral blood flow in patients with chronic cerebral ischemia].
Grigor'eva AN; Nesterova MV
Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7):90-1. PubMed ID: 19708280
[No Abstract] [Full Text] [Related]
34. Galantamine treatment in outpatients with mild Alzheimer's disease.
Richarz U; Gaudig M; Rettig K; Schauble B
Acta Neurol Scand; 2014 Jun; 129(6):382-92. PubMed ID: 24461047
[TBL] [Abstract][Full Text] [Related]
35. [Validation of the Hungarian version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild cognitive impairment].
Papp E; Pákáski M; Drótos G; Kálmán J
Psychiatr Hung; 2012; 27(6):426-34. PubMed ID: 23429337
[TBL] [Abstract][Full Text] [Related]
36. [Vinpotropil in the treatment of dyscirculatory encephalopathy with cognitive impairment without dementia].
Zakharov VV
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(11 Pt 1):13-6. PubMed ID: 21183916
[TBL] [Abstract][Full Text] [Related]
37. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.
Guekht AB; Moessler H; Novak PH; Gusev EI;
J Stroke Cerebrovasc Dis; 2011; 20(4):310-8. PubMed ID: 20656516
[TBL] [Abstract][Full Text] [Related]
38. The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES).
Chen CL; Ikram K; Anqi Q; Yin WT; Chen A; Venketasubramanian N;
Cerebrovasc Dis; 2013; 35 Suppl 1():23-9. PubMed ID: 23548916
[TBL] [Abstract][Full Text] [Related]
39. Combination of Vinpocetine and Dexamethasone Alleviates Cognitive Impairment in Nasopharyngeal Carcinoma Patients following Radiation Injury.
Zhang P; Cao Y; Chen S; Shao L
Pharmacology; 2021; 106(1-2):37-44. PubMed ID: 32294652
[TBL] [Abstract][Full Text] [Related]
40. Hierarchical Bayesian cognitive processing models to analyze clinical trial data.
Shankle WR; Hara J; Mangrola T; Hendrix S; Alva G; Lee MD
Alzheimers Dement; 2013 Jul; 9(4):422-8. PubMed ID: 23123230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
